Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma

  • Alessandro Rizzo
    Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy
    Search for articles by this author
Published:October 08, 2022DOI:
      To the editor
      To read this article in full you will need to make a payment
      ESMO Member Login
      Login with your ESMO username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Corrie P.
        • Meyer N.
        • Berardi R.
        • Guidoboni M.
        • Schlueter M.
        • Kolovos S.
        • et al.
        Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
        Cancer Treat Rev. 2022; 110: 102463
        • Higgins J.P.
        • Jackson D.
        • Barrett J.K.
        • Lu G.
        • Ades A.E.
        • White I.R.
        Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.
        Res Synth Methods. 2012 Jun; 3: 98-110
        • Rouse B.
        • Chaimani A.
        • Li T.
        Network meta-analysis: an introduction for clinicians.
        Intern Emerg Med. 2017; 12: 103-111

      Linked Article